Impact of Handling Perception and Language Barriers on Virologic Response to Daily Subcutaneous Bulevirtide in Hepatitis D.

ABSTRACT:

Background

Bulevirtide (BLV) is the only approved therapy for chronic hepatitis D (CHD) and compensated liver disease. Daily subcutaneous injection and the need for refrigeration may pose challenges, especially in patients with limited language proficiency.

Aims

Assessment of patient-reported BLV handling and satisfaction and association with virologic response.

Methods

Patients receiving BLV were assessed using a structured questionnaire on injection preparation, administration, refrigeration, adverse effects, and language proficiency. Virologic response was defined as complete (≥ 2 log10 reduction from baseline or HDV RNA undetectable), intermediate (≥ 1 log10 but < 2 log10 reduction), non-response (< 1 log10 reduction or increase), or breakthrough (> 1 log10 increa

SUBMITTER: Herta T 

PROVIDER: S-EPMC12535276 | biostudies-literature | 2025 Nov

REPOSITORIES: biostudies-literature